Esketamine Therapy

Esketamine Therapy is a pharmacotherapeutic intervention that belongs to the class of glutamatergic rapid-acting antidepressant treatments, distinguished by its administration of the S-enantiomer of ketamine as a nasal spray formulation to alleviate treatment-resistant depression in conjunction with an oral antidepressant.

223

Publications

14.7K

Citations

1.2K

Authors

480

Institutions

Publications per year

2017–2026

219

Publications

223

1–5 of 223

Authors

1.2K

  1. JS
    Jaskaran Singh

    Janssen (United States), United States

    30 publications · 5.7K citations

    23

    h-index

  2. WC
    Wayne C. Drevets

    National Institute of Mental Health, United States

    23 publications · 6.2K citations

    19

    h-index

  3. ED
    Ella Daly

    Janssen (United States), United States

    23 publications · 4.6K citations

    18

    h-index

  4. RL
    Rosanne Lane

    Janssen (United States), United States

    17 publications · 4.9K citations

    17

    h-index

  5. PL
    Pilar Lim

    Johnson & Johnson (United States), United States

    15 publications · 5.3K citations

    14

    h-index

1–5 of 1.2K

Venues

  1. Journal of Affective Disorders

    15 publications · 824 citations

    13

    h-index

  2. BMC Anesthesiology

    14 publications · 378 citations

    13

    h-index

  3. Drug Design Development and Therapy

    9 publications · 548 citations

    9

    h-index

  4. Frontiers in Psychiatry

    9 publications · 284 citations

    9

    h-index

  5. Psychiatry Research

    7 publications · 261 citations

    7

    h-index

1–5